Home > Riviste > Minerva Pediatrica > Fascicoli precedenti > Minerva Pediatrica 2018 June;70(3) > Minerva Pediatrica 2018 June;70(3):207-11

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE   

Minerva Pediatrica 2018 June;70(3):207-11

DOI: 10.23736/S0026-4946.16.04688-0

Copyright © 2016 EDIZIONI MINERVA MEDICA

lingua: Inglese

Evaluation of clinical outcome in children and adolescents receiving vancomycin for invasive infections due to methicillin-resistant Staphylococcus aureus: impact of increasing vancomycin MICs

Aparna ARUN 1, Siddharth SWAMY 2, Kathleen JACOB 3, Roopali SHARMA 2, 4, Stephan A. KOHLHOFF 1, Margaret R. HAMMERSCHLAG 1

1 Department of Pediatrics, SUNY Downstate Medical Center, Brooklyn, NY, USA; 2 Department of Pharmacy Practice, SUNY Downstate Medical Center, Brooklyn, NY, USA; 3 Department of Clinical Laboratories, SUNY Downstate Medical Center, Brooklyn, NY, USA; 4 Touro College of Pharmacy, New York, NY, USA


PDF


BACKGROUND: Vancomycin is the preferred drug for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in children. In adults, treatment failure with vancomycin has been associated with an area under the curve/24 hrs /MIC (AUC24/MIC) ratio of ≤400 and high minimum inhibitory concentrations (MIC ≥1.0 mg/L). Vancomycin dosing information to ensure optimal AUC24/MIC in the pediatric population remains limited.
METHODS: A retrospective chart review from August 2008 to 2011 and a prospective study from September 2011 to October 2013 was conducted on all pediatric patients at two hospitals in Brooklyn, NY with positive cultures for MRSA who received vancomycin. Treatment failure was defined as persistent positive cultures (≥5 days) or persistence of clinical symptoms. Vancomycin AUC24/MICs were calculated.
RESULTS: Twenty-three children with MRSA infection, 0-18 years of age, were identified; 18 of 23 (78.3%) were community acquired. MICs of 91% of the isolates were ≥1.5 µg/mL and 9 had MICs of 2 µg/mL. Treatment failure was seen in 12 (52%) patients with MICs of 1.5 µg/mL and above. Vancomycin trough levels >15 µg/mL and AUC24/MIC >400 were achieved in only 18% and 0% of patients, respectively.
CONCLUSIONS: High treatment failure rates with vancomycin was associated with MIC ≥1.5 µg/mL. Current recommended vancomycin dosing in children did not achieve a trough concentration of >15 µg/mL in majority of the patients and none achieved an AUC24/MIC>400.


KEY WORDS: Vancomycin - Methicillin-resistant Staphylococcus aureus - Microbial sensitivity tests

inizio pagina